Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Alopecia Clinical Trials

A listing of Alopecia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8) clinical trials

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to 50 years of age with 25% scalp hair loss due to Alopecia Areata (AA).

Phase

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams [mg]) in participants with moderate-to-severe alopecia areata.

Phase

A Phase II Study in Patients With Alopecia Areata

The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 3 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, …

Phase

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

Male pattern hair loss (MPHL) is a common, frustrating, and difficult to manage scalp disease with few treatment options available. Though the mechanism remains unclear, minoxidil is a well-established treatment for MPHL. With the advent of laser assisted drug delivery, the investigators seek to investigate the use of laser assisted …

Phase

Topical Crisaborole in Patients With Alopecia Areata

Each individual will be enrolled in the study for 24 weeks. Following a 28 days screening period, eligible subjects will be randomized in a 1:1 ratio to receive either crisaborole 2% ointment or matching placebo for 12 weeks. The primary endpoint is assessed at week 12. At the week 12 …

Phase

Tofacitinib for Immune Skin Conditions in Down Syndrome

Trisomy 21 (T21) is the most common human chromosomal disorder, occurring in ~1/700 live births, leading to the condition known as Down syndrome (DS). Importantly, people with DS display widespread immune dysregulation and over half of adults with T21 are affected by one or more autoimmune conditions, including several immune …

Phase

Jaktinib Dihydrochloride Monohydrate in Severe Alopecia Areata

Clinical trial of Tofacitinib, Ruxolitinib, and Baricitinib have shown promising prospects for the treatment of alopecia areata (especially severe alopecia areata) with JAK inhibitorsJaktinib Dihydrochloride Monohydrate is a potent inhibitor of JAK1 JAK2 and JAK3This was a phase , open-label, Multi-center,randomized study to Evaluating Safety and Efficacy of oral Jaktinib …

Phase

ENERGI-F701 for Female Hair Loss Treatment

The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.

Phase